logo

Avacta Group - Exciting partnership with Bach BioSciences

Written by Riccardo Lowi

Avacta Group Plc (LON:AVACT) has recently finalised a co-development partnership with Boston-based Bach BioSciences, to exploit the potential of the Affimer platform for the development of a novel class of drug conjugates.

Despite the favourable reaction to the announcement of the Bach Biosciences agreement (stock up 35%), Avacta’s market capitalisation is still much lower than biotech peers  that have unique protein-based platforms and drug candidates in the clinical stage, where Avacta is on track to be by 2020.

FULL REPORT CONTINUES…

Latest Research